The role of short-chain fatty acids on insulin sensitivity: a systematic review and meta-analysis

Nhan H.T. Pham[1,2*], Mugdha V. Joglekar[1*], Wilson K.M. Wong[1], Najah T. Nassif [2], Ann M. Simpson [2], and Anandwardhan A. Hardikar[1,3,4]

[1] Diabetes and Islet Biology Group, School of Medicine, Western Sydney University, Campbelltown, NSW 2560. Australia.

[2] School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.

[3] Department of Science and Environment, Roskilde University, Roskilde, Denmark.

*Contributed equally and are equal first authors

[4]Address all correspondence to:

Anandwardhan A. Hardikar, PhD

Diabetes and Islet Biology Group, School of Medicine, Western Sydney University,

30.2.27 Goldsmith & David Pilgrim Ave, Campbelltown, NSW 2560, AUSTRALIA

Phone: +61 2 9562 5071 | Fax: +61 2 9565 1863

E-mail: a.hardikar@westernsydney.edu.au or anand@isletbiology.info

Web: https://www.isletbiology.info/

Article type: Meta-analysis

Keywords: acetate, propionate, butyrate, SCFA, type 2 diabetes, HOMA-IR, insulin sensitivity.

Abstract

Context: There is substantial evidence that reduced gut short chain fatty acids (SCFAs) are associated with obesity and type 2 diabetes, although findings from clinical interventions that could increase SCFAs are inconsistent.

Objective: This work aimed to assess the effect of SCFA intervention on fasting glucose, fasting insulin, and HOMA-IR by performing a systematic review and meta-analysis.

Data sources: Relevant published articles up to 28th July 2022 were extracted from PubMed and EMBASE using the medical subject heading (MeSH) of the defined keywords [(short-chain fatty acids AND (obesity OR diabetes OR insulin sensitivity)] and their synonyms. Data analyses were performed using recommended Cochrane meta-analysis checklist and PRISMA guidelines and were registered in the PROSPERO system (ID: CRD42021257248).

Data extraction: Clinical studies and trials that measured SCFAs along with reporting glucose homeostasis parameters were included in the analysis. Standardized mean differences (SMD) with 95% confidence intervals (CI) were calculated using a random-effects model in the data extraction tool Review Manager version 5.4 (RevMan 5.4). The risk of bias assessment was performed following the Cochrane checklist for randomised and crossover studies.

Data analysis: We identified 6,040 non-duplicate studies; 23 met defined criteria and reported fasting insulin, fasting glucose, or HOMA-IR as well as a measured post-intervention change in SCFA concentrations. Our meta-analyses indicated that fasting insulin concentrations significantly reduced (overall effect: SMD = -0.15; 95% CI = -0.29, -0.01, p = 0.04) between placebo and treatment groups at the end of the intervention. Post-intervention increase in SCFAs had an even significant effect on lowering fasting insulin (p=0.008). Elevated levels of SCFAs were also associated with beneficial effects on HOMA-IR (p < 0.00001) compared to their baseline. Fasting glucose concentrations did not show any significant change.

Conclusions: Increased post-intervention SCFA is associated with lower fasting insulin, offering a beneficial effect on insulin sensitivity.

Introduction

Type 2 diabetes mellitus (T2D) is characterised by a reduction in β-cell function as well as insulin resistance, wherein skeletal muscle, liver, and adipocytes cannot uptake sufficient amounts of glucose [1]. T2D leads to life-threatening complications such as neuropathy, retinopathy, and cardiovascular diseases. According to the World Health Organization, there are over 537 million adults living with T2D and this number is estimated to reach 783 million by 2045 [2].

Along with T2D, overweight (body mass index/BMI of 25 to <30) and obesity (BMI ≥ 30) are considered major health problems, currently affecting approximately two billion people worldwide [3,4]. Obesity is a major health risk for the development of cardiovascular disease, hypertension, and stroke. It is also known to dramatically increase the risk of T2D, wherein 90% of individuals with T2D are obese or overweight [5]. Beneficial effects of gut microbiota and short-chain fatty acids (SCFAs) on metabolic health in obesity [6,7] and T2D [8,9], have been reported. The diversity in the gut microbiome is well recognised between lean and obese individuals [6,7] as well as between individuals with and without diabetes [10,11]. Gut microbes produce SCFAs, mainly acetate, propionate, and butyrate, through the fermentation of resistant starch or soluble fibre. These molecules are shown to induce the expression of gut hormones such as peptide tyrosine-tyrosine (PYY) and glucagon-like peptide 1 (GLP-1) via free fatty acid receptors (G-Protein Coupled Receptor, GPR 41/43) [12,13], leading to appetite suppression [14] and improvement of glucose tolerance and insulin sensitivity [15,16]. In addition, it has been shown that fecal transplantation from lean donors to obese recipients altered their gut microbial composition and improved insulin sensitivity [17,18].

SCFAs can be administered directly, as sodium salts or esters, or indirectly as pre-/probiotics or high-fibre diets. Multiple clinical trials have aimed at improving SCFAs in participants with impaired insulin sensitivity, pre-existing overweight/obesity, and multiple gastrointestinal abnormalities. Many meta-analyses are available on the topic of SCFAs in human clinical trials, however, most of these focus on irritable bowel disease [19-21], inflammatory markers [22,23], obesity [24,25], or gut biota [26,27]. Relevant previous

meta-analyses (**Table S1**) report effects on insulin and glucose concentrations after consumption of specific diet such as fibre, resistant starch or wholegrains [28-33] or synbiotics [34] and probiotics [35,36]. Changes in total SCFAs were analysed only in one review along with *Bifidobacteria* and fasting glucose [33]; however this study did not examine the effect of SCFA changes on fasting insulin or HOMA-IR. To our knowledge, there is no systematic review and meta-analyses that assessed the effects of post-intervention changes in SCFAs on insulin sensitivity in humans. To address this research gap, we analysed clinical studies (randomised clinical trials, observational, or treatment-only studies) that reported actual values of either glucose, insulin, or HOMA-IR as well as measured SCFAs following interventions. Our systematic review and meta-analysis are inclusive of different interventions that have the potential to alter SCFAs and are focussed on studies that confirm a change in SCFA concentrations post-intervention.

Methods

Data sources and search

We carried out a systematic search using PubMed and EMBASE via Ovid for studies published from January 01, 1959, to July 28, 2022. There were no restrictions on the use of Medical Subject Heading (MeSH) terms and their synonyms. The keywords used for the literature search were "short-chain fatty acids AND (obesity OR diabetes OR insulin sensitivity)". All studies were screened based on their title, abstract, and full-text (**Figure 1**), following the recommended Cochrane meta-analysis checklist and PRISMA guidelines [37]. Search strategy, study eligibility, data extraction, and analysis of this systematic review were pre-registered in the PROSPERO system (ID: CRD42021257248).

Inclusion and Exclusion criteria

Papers were included for screening if they contained the keywords (as defined in the literature search section above) and PICOS criteria summarised in **Table 1**. Exclusion criteria were defined as (1) not human studies such as animal studies or cell culture studies, (2) not published in the English language,

and (3) publication types other than peer-reviewed original papers, such as systematic reviews, meta-analysis, reviews, conference publications, non-article papers, generic writing, thesis chapters, and case reports, (4) not providing data for fasting glucose, fasting insulin or HOMA-IR, and (5) not reporting SCFA concentrations pre- and post-intervention.

Data extraction

Results from the search were added to an EndNote X8 [38] (Clarivate Analytics, Toronto, Canada) library and in an MS-Excel worksheet for data screening and extraction (**Figure 1**). The first step of removing duplicate hits from the two databases EMBASE and PubMed was performed in the EndNote library, where papers with identical titles and authors were marked as duplicates and removed. In the screening step, titles and abstracts were assessed for eligibility, and articles were excluded if they met any of the exclusion criteria. The 23 qualifying papers were then reviewed in full-text versions and included in the meta-analysis that were 1) original human clinical studies, 2) provided values (not AUCs or coefficients) of fasting glucose, insulin, and/or insulin resistance score/HOMA-IR, and 3) verified plasma/faecal SCFAs before and/or after the intervention. All values were converted to mean ± SD, mmol/L for glucose, and μU/mL for insulin. Reported units for glucose and insulin were made consistent [39]. In two [40][41] of the 23 studies, units or standard deviation values were confirmed with the authors of the original articles via email correspondence. Sub-group analyses were performed to investigate differences in fasting insulin, glucose, or HOMA-IR between placebo and treatment groups, or between the baseline and the endpoint. Two researchers (NHTP and MVJ) performed the search and data extraction independently and then cross-checked.

Quality of Evidence and Risk of Bias

The assessments of risk of bias and quality of evidence were conducted following the Cochrane recommendations [42], and outcomes were presented using RevMan (Version 5.4, The Cochrane Collaboration, 2020) [43]. The criteria included random sequence generation (selection bias), allocation

concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective bias (reporting bias), and other bias. Each criterion was assigned as either high risk, low risk, or unclear. Treatment-only studies were not included in the selection, performance, and detection bias as all participants and associated clinicians were aware of treatment allocation. Several of the studies had a crossover design. Therefore, we also assessed three additional criteria for crossover studies including appropriate crossover design, carry-over effects, and unbiased data (reporting data at all stages of the trial) [44].

Data Synthesis and Statistical analysis

Data synthesis and statistical analysis were carried out using Microsoft Excel (MS-Excel ver. 2016; Microsoft Corporation, Redmond, WA, USA) and RevMan 5.4. MS-Excel was used to tabulate and/or summarize the data collected, for calculating insulin and glucose values at appropriate units as well as to plot stacked bar graphs. RevMan 5.4 software was used to produce forest plots. All data were entered as mean$\pm$ SD. Standardized mean differences (SMD) with 95% confidence intervals (CI) using the random effects model and inverse variance statistical method were performed between the placebo group and the intervention group, or between the baseline and the endpoint. We also carried out the same analysis using the fixed effects model to ensure the robustness of our calculations. All the analyses were performed in RevMan 5.4. A P-value < 0.05 was considered as significant. SMD values for SCFAs, insulin, and glucose were calculated in RevMan 5.4 software and used for Spearman correlation analysis. Correlation matrix was generated using corrplot (0.92), Hmisc (4.6.0), dplyr (1.0.7) packages and R (version 3.6.1) in Rstudio (2021.09.0, Build 351, R Foundation for Statistical Computing, Vienna, Austria). The correlation significance was analysed and verified on GraphPad Prism version 9.4.1 (GraphPad Software, San Diego, CA, USA).

Results

Characteristics of studies included for meta-analysis

The PRISMA flow diagram for the stepwise selection of studies is shown in **Figure 1**. The initial search using the defined MeSH terms in PubMed and EMBASE via Ovid identified 6,040 papers (after excluding 907 duplicates). In the screening step, 570 articles were removed as they were non-English papers or non-journal articles. Following title and abstract screening on the remaining 5,470 papers, 278 papers were deemed eligible for full-text assessment. A majority (198 studies) of these studies did not perform insulin sensitivity/resistance tests while 49 papers did not present quantitative data on fasting insulin or fasting glucose and were therefore removed from the meta-analysis. Twenty-three studies were included in the final selection (**Table 2**) that contained actual values for fasting glucose and insulin, and therefore included in the meta-analysis [40,41,45-65].

Table 2 summarises the 23 studies used in the meta-analysis. Analyses include data on a total of 1,186 study participants from all categories (healthy 12%, obese/overweight 67%, and people with underlying conditions including diabetes 21%). Out of the 23 studies, 17 had dietary interventions, four studies provided propionate as inulin propionate ester, and one study had gastric bypass treatment, while the other study had sodium acetate infusion. Most of the studies followed intervention for as little as 10 days and up to six months, while only four studies had interventions for less than one-week duration. Either one or all the three major SCFAs (acetate, propionate, and butyrate), from plasma or faeces, were measured in all studies using chromatography, spectroscopy, or enzymatic methods. Although these 23 papers measure plasma/faecal SCFAs, few of these do not report the actual SCFA concentrations. It was therefore difficult to perform a meta-analysis for SCFA concentrations in different interventions. We, therefore, divided our analysis into two subgroups (one with increased SCFAs and the other without increased SCFA at the end of the intervention; **Figures 2 to 4**).

Changes in glucose homeostasis parameters between placebo and intervention groups at the endpoint

The effects of SCFAs on fasting insulin (**Figure 2**), fasting glucose (**Figure 3**), and HOMA-IR (**Figure 4**), are stratified for studies (from **Table 2**) that confirm a significant increase or no change in SCFA concentrations post-intervention. In a comparison between placebo and intervention groups at the endpoint (final assessment after intervention), fasting insulin was significantly lower (SMD = -0.25; 95% CI = -0.43, -0.06; p = 0.008) in the treatment group when SCFA concentrations were confirmed to have increased at the end of intervention (**Figure 2**). The overall effect on fasting insulin concentrations was also significant (SMD = -0.15; 95% CI = -0.29, -0.01; p = 0.04; **Figure 2**). In contrast, fasting glucose (SMD = -0.06; 95% CI = -0.24, 0.13, p = 0.55; **Figure 3**) and HOMA-IR (SMD = -0.22; 95% CI = -0.48, 0.05, p = 0.11; **Figure 4**) did not differ significantly between treatment and control arms for studies wherein SCFA concentrations increased post-intervention. For the subgroup of studies without increase in SCFAs, there were no significant differences in fasting insulin, fasting glucose, and HOMA-IR between the control and treatment arms (**Figures 2 to 4**).

When fasting insulin values were analysed based on direct SCFA or indirect dietary treatment, a significant reduction of fasting insulin was observed only after direct intervention (SMD = -0.39; 95% CI = -0.74, -0.05; p = 0.03) but not after the indirect (dietary) intervention compared to their controls (**Figure S1**). Further subgrouping into direct intervention with evidence of increased SCFAs showed significant reduction of fasting insulin (SMD = -0.58; 95% CI = -1.01, -0.16; p = 0.007) (**Figure S2**). However, it should be noted that all the three studies included in this analysis were from the same group and for inulin-propionate ester intervention [49,50,64]. Similar sub analyses for the source of SCFA measurement (faecal or plasma) revealed that elevated plasma SCFAs were associated with a significant reduction in fasting insulin concentrations (SMD= -0.22, 95% CI = -0.43, -0.01, p= 0.04: **Figure S3**). Since the beneficial effects on glycemic parameters were seen when SCFAs were higher, we performed a correlation analysis on the changes in SCFA, insulin, and glucose concentrations between placebo and

intervention at the endpoint (**Figure S4**). Out of the 23 studies, only 8 studies could be included for this analysis as only those reported the actual values of SCFA concentrations (**Table S2**). Notably, we found that the standardised mean difference (SMD) of acetate between the placebo and intervention group was significantly and inversely correlated with that of fasting insulin (r=-0.64, p=0.048).

Improvement in glucose-insulin measurements relative to study baseline

We also analysed changes in fasting insulin, glucose as well as HOMA-IR, with reference to their baseline measurements in the intervention group and the placebo group. A significantly lower fasting insulin was observed at the end of intervention (**Figure 5**) compared to baseline (SMD = -0.22; 95% CI = -0.43, -0.01; p = 0.04) in studies that confirm increased SCFA concentrations. The overall effect on fasting insulin was also significant when all studies were included (SMD=-0.18, 95% CI = -0.34, -0.03, p=0.02: **Figure 5**). Fasting glucose did not demonstrate any significant changes relative to baseline in the meta-analysis (**Figure 6**). On the other hand, HOMA-IR was significantly different (SMD = -0.44; 95% CI = -0.56, -0.32; p < 0.00001) in studies with increased post-intervention SCFA concentrations. This significance was also observed when all the studies (demonstrating increased/no-change/decreased SCFAs post-intervention) were included in the analysis (SMD = -0.37; 95% CI = -0.48, -0.27; p <0.00001) (**Figure 7**). In our analysis for HOMA-IR, one study [53], had more participants than others. Baseline versus endpoint comparison in the placebo group alone did not demonstrate any significant improvement in fasting insulin, fasting glucose, and HOMA-IR (**Figure S5, S6 and S7**) respectively.

Risk of bias assessment

The quality assessment of the 23 papers included in the meta-analysis is presented in **Figure S8**. As mentioned in the methods section, crossover studies were analysed separately [45-47,49,52,55-57,61,62] (**Figure S8A**). Several of the studies did not report sufficient details of unbiased data presentation or carry-over effects to assign low or high risks, therefore, they had to be classified as unclear risks. Allocation concealment criteria was not described in 80% of the papers and is the highest factor with unclear risks.

Similarly, unbiased data (availability of study results at every time point during crossover) reporting was not clear in most of the studies. A high risk of bias was largely found for blinding criteria. Since most of the studies are dietary interventions, blinding may not be always applicable (i.e. the participants and the researchers could see what foods were given). In the parallel-arm trials, the risk of bias was much lower in most of the studies (**Figure S8B**). Five treatment-only studies [40,41,51,53,54] were not included for selection, performance, and detection bias analyses, since all participants received the same treatment, and any selection/blinding was not applicable. These studies are denoted by the white area in the graphs (**Figure S8B**).

Discussion

This systematic review included 23 papers in the meta-analysis consisting of a varied group of participants. The main finding was significantly lower fasting insulin in the intervention group that received SCFAs directly, as well as in the group that had evidence of an increase in SCFAs following intervention compared to the placebo group. When treatment baseline and endpoint values were compared, fasting insulin and HOMA-IR were significantly improved at the endpoint, which was not observed for the placebo baseline vs endpoint comparison. Similar results were achieved when using the fixed effects model, thus confirming the robustness of this study.

The underlying mechanism linking SCFAs to T2D has not been fully elucidated. A mechanism involving gut microbes/microbial metabolites (eg. colonic SCFAs) regulating incretin hormone expression, insulin secretion, and glucose homeostasis is likely and needs validation. Incretin hormones such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are known to regulate insulin secretion following oral glucose intake [66]. GLP-1 also plays a significant role in improving glucose tolerance and insulin sensitivity [15,16]. Interestingly, SCFAs lowered fasting insulin and improved HOMA-IR, without affecting fasting glucose. It would have been informative to understand the effects of the increase in SCFAs on GLP-1 concentrations, however only six studies

performed GLP-1 measurements [47-49,58,61,62], and only three of these studies mentioned the use of the necessary dipeptidyl peptidase 4 (DPP-4) inhibitors during the collection of samples [48,61,62]. Meta-analysis to understand the effect of changes in SCFAs on GLP-1 was inconclusive in this same set of papers.

Sodium acetate was the first SCFA to be applied in human studies in the 1980s via gastric or IV infusion with various dosages [67-70]. Notably, most of the studies during the last decade have focused on the use of sodium propionate, sodium butyrate, or SCFA mixtures via the oral route for extended periods of time (up to 6 months), with dosages ranging from 1-10 g per day. These studies, and the long periods of SCFA intervention underscores their safety in human clinical studies/trials. To date, there have been no reports of any adverse side effects of SCFAs on human health. A very recent systematic review and meta-analysis assessed the effects of acute and chronic administration of SCFAs and vinegar on glycemic control [71]. Interestingly, they did not observe a significant effect of acute acetate and propionate as well as chronic propionate treatment on glucose and insulin concentrations. However, this study did not stratify their analyses based on changes in SCFA concentrations post-intervention. Based on our quantitative analysis, only those studies with evidence of increase in SCFA concentrations had significantly lower fasting insulin, whereas studies without increase in SCFAs did not change insulin concentrations.

SCFAs are typically measured in faecal or plasma samples. In faeces, they are present in larger quantities[72] and faecal SCFAs are considered as an indirect representation of SCFA production in the colon. SCFAs that are present in the circulation are in smaller quantities and usually reflect the amount that is remaining after their uptake in colonocytes and then in the liver[73]. Nonetheless, circulating SCFAs are shown to be better associated with metabolic health than faecal SCFAs [74]. Our sub-analysis also confirmed significant effect on fasting insulin concentrations when circulating SCFAs are increased. One of the potential reasons for higher variability in faecal SCFAs could be the sample

collection, storage, and processing methods [75]. Standardisation of approaches in SCFA measurements are urgently needed.

Our meta-analysis identified that direct administration of SCFAs is beneficial than indirect methods including varied diets. It is notable that the use of SCFAs via oral administration is not favourable due to their unpleasant taste and odour[76]. Recent studies have been developing novel targeted delivery systems that can deliver SCFAs into the colons or the circulating system [77]. In our analysis, there was only one study that had a direct infusion of SCFAs (i.e., acetate infusion) [40] and reported increases in circulating (plasma/serum) SCFAs. All the remaining studies that provided SCFAs as either capsules or powders or meals reported variable SCFA concentrations [47,49,50,64] at the endpoint. Apart from potential differences in faecal and circulating SCFA concentrations, another reason for this variation could be a different method of compliance assessment. Three trials [49,50,64] maintained regular communication between participants and investigators to encourage high compliance, and the participants returned their used and unused sachets to calculate the compliance rate at the end of the study. Future studies should ensure that compliance with intervention is assessed and reported.

Due to the invasive nature of infusion studies, the direct infusion of acetate was performed for a short period of time [40]. However, studies that confirmed an increase in SCFA concentrations, were the ones that reported a lowering effect on fasting insulin. Therefore, it would be interesting to understand the long-term effects of SCFA infusion on insulin sensitivity. Clinical trials addressing this question are warranted. Interestingly, a separate systematic review and meta-analysis confirmed that the left colon may contribute to the maintenance of glucose homeostasis [78]. Since human GLP-1-producing L-cells are found at the highest density in the left colon [79], removal of the left colon is, not surprisingly, associated with T2D. SCFAs provide a unique opportunity to manipulate the expression of incretin hormone expression and more studies in this area are needed.

Limitations: Limitations of this meta-analysis are mainly due to the heterogeneity, which was unavoidable due to the nature of our study question on SCFAs and insulin sensitivity. The factors contributing to the high heterogeneity were age, sex, sample size, diet, lifestyle, background health conditions, types of SCFAs measured (acetate/propionate/butyrate/all) as well as a source of SCFAs (faeces/plasma). Heterogeneity is also in the types of interventions in the 23 studies that included different kinds of diets, SCFAs as capsules/infusion, or gastric bypass surgery. We were unable to perform sub-analyses such as understanding the effects of SCFA dosage or SCFA delivery route on fasting insulin and fasting glucose, due to fewer number of studies. It is also notable that majority of the studies in this analysis were conducted in three continents (Europe, the USA, and Australia), which may contribute to the risk of bias in the recruitment of individuals with a Caucasian background. However, the ethnicity of participants was not mentioned in all the studies. We recognize the differences in sensitivities of the methods used for SCFA and insulin/glucose measurement. Also, we conducted a literature search which was limited to papers published in English only, thus 169 non-English papers were excluded.

Strengths: Despite the limitations, this is the first systematic review to summarise and provide a meta-analysis of clinical studies with the potential of increasing SCFAs. Our meta-analysis captured all studies that reported SCFA measurements and provided actual values of fasting insulin and glucose in humans. This approach was chosen as the focus of our systematic review and meta-analysis was to understand the metabolic benefits of elevated SCFA following clinical interventions.

Conclusion

To our knowledge, this is the first meta-analysis that demonstrates a significant lowering in fasting insulin when SCFA concentrations were confirmed to have increased. Whilst such beneficial effect of SCFAs on fasting insulin has been confirmed, several factors need to be evaluated before optimal implementation such as the type of SCFA (acetate/propionate/butyrate/mixture), a form of SCFA

capsules (sodium salts, inulin esters, or fibre-enriched diets), duration, and route of delivery (oral, or IV infusion) as well as compliance. Nonetheless, based on the overall results, direct SCFA consumption or a SCFA-enriched diet was found to have beneficial effects on fasting insulin. Therefore, SCFA interventions, or dietary guidance along with clinical monitoring and lifestyle management, could be considered a safe and novel treatment for overweight, obese, or subjects with type 2 diabetes.

Acknowledgments:

The authors acknowledge the infrastructure support through the Western Sydney University School of Medicine and the library services through the University of Technology Sydney.

Funding:

NHTP acknowledges a scholarship from the Islet Biology group and support through Diabetes Australia (General Grant award to MVJ). MVJ was supported through a JDRF International Advanced Post-doctoral award (3-APF-2016-178-A-N) and a transition award from JDRFI (1-FAC-2021-1063-A-N). WKMW is supported through the Leona M. and Harry B. Helmsley Charitable Trust (Grant 2018PG-T1D009 to AAH) in collaboration with the JDRF Australian Type 1 Diabetes Clinical Research Network funding (Grant 3-SRA-2019-694-M-B to AAH). AAH is supported by grants from Juvenile Diabetes Research Foundation (JDRF) Australia T1D Clinical Research Network (JDRF/4-CDA2016-228-MB) and Visiting Professorships (2016-18 and 2019-22) from the Danish Diabetes Academy, funded by the Novo Nordisk Foundation, grant number NNF17SA0031406.

Declaration of Interest:

No potential conflicts of interest relevant to this article were reported

Author contributions:

Conceptualization: AAH; Original search and analysis: NHTP; Validation: MVJ; Writing- first draft: NHTP, MVJ; Writing- review and editing: WKMW, NTN, AMS, AAH; Writing- finalisation: AAH. Revisions: All authors. AAH is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Supporting Information: PRISMA checklist, 2 supplementary tables, and 8 supplementary figures

References

1.   Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. *Diabetic medicine*. 1998;15(7):539-553.

2.   Federation ID. IDF Diabetes Atlas 9th edn. 2019;

3.   Federation ID. IDF Diabetes Atlas 10th edn. 2021;

4.   Organization WH. Obesity and overweight. Fact sheet no. 311. Updated January 2015.

5.   Bramante CT, Lee CJ, Gudzune KA. Treatment of obesity in patients with diabetes. *Diabetes Spectrum*. 2017;30(4):237-243.

6.   Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. *Nature*. 2013;500(7464):585-588.

7.   Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013;500(7464):541-546.

8.   Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. *Nature*. 2013;498(7452):99-103.

9.   Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. *Nature*. 2012;490(7418):55-60.

10.   Larsen N, Vogensen FK, Van Den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PloS one*. 2010;5(2):e9085.

11.   Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. *nature*. 2009;457(7228):480-484.

12.   Kimura I, Ozawa K, Inoue D, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nature communications*. 2013;4(1):1-12.

13.   Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *Journal of Biological Chemistry*. 2003;278(13):11312-11319.

14.   Horner K, Lee S. Appetite-related peptides in childhood and adolescence: role of ghrelin, PYY, and GLP-1. *Applied Physiology, Nutrition, and Metabolism*. 2015;40(11):1089-1099.

15.   Cani PD, Knauf C, Iglesias MA, Drucker DJ, Delzenne NM, Burcelin R. Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor. *Diabetes*. 2006;55(5):1484-1490.

16.   Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. *The Lancet*. 2002;359(9309):824-830.

17.   Kootte RS, Levin E, Salojärvi J, et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. *Cell metabolism*. 2017;26(4):611-619. e6.

18.   Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology*. 2012;143(4):913-916. e7.

19.   Sun Q, Jia Q, Song L, Duan L. Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis. *Medicine*. 2019;98(7)

20.   Zhuang X, Li T, Li M, et al. Systematic review and meta-analysis: short-chain fatty acid characterization in patients with inflammatory bowel disease. *Inflammatory bowel diseases*. 2019;25(11):1751-1763.

21.   Shen D, Bai H, Li Z, Yu Y, Zhang H, Chen L. Positive effects of resistant starch supplementation on bowel function in healthy adults: a systematic review and meta-analysis of

randomized controlled trials. *International Journal of Food Sciences and Nutrition*. 2017;68(2):149-157.

22.   McLoughlin RF, Berthon BS, Jensen ME, Baines KJ, Wood LG. Short-chain fatty acids, prebiotics, synbiotics, and systemic inflammation: a systematic review and meta-analysis. *The American journal of clinical nutrition*. 2017;106(3):930-945.

23.   Tabrizi R, Ostadmohammadi V, Lankarani KB, et al. The effects of probiotic and synbiotic supplementation on inflammatory markers among patients with diabetes: A systematic review and meta-analysis of randomized controlled trials. *European journal of pharmacology*. 2019;852:254-264.

24.   John GK, Wang L, Nanavati J, Twose C, Singh R, Mullin G. Dietary alteration of the gut microbiome and its impact on weight and fat mass: a systematic review and meta-analysis. *Genes*. 2018;9(3):167.

25.   Hadi A, Alizadeh K, Hajianfar H, Mohammadi H, Miraghajani M. Efficacy of synbiotic supplementation in obesity treatment: a systematic review and meta-analysis of clinical trials. *Critical reviews in food science and nutrition*. 2020;60(4):584-596.

26.   So D, Whelan K, Rossi M, et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. *The American journal of clinical nutrition*. 2018;107(6):965-983.

27.   Kim KN, Yao Y, Ju SY. Short chain fatty acids and fecal microbiota abundance in humans with obesity: A systematic review and meta-analysis. *Nutrients*. 2019;11(10):2512.

28.   Kellow NJ, Coughlan MT, Reid CM. Metabolic benefits of dietary prebiotics in human subjects: a systematic review of randomised controlled trials. *British Journal of Nutrition*. 2014;111(7):1147-1161.

29.   Marventano S, Vetrani C, Vitale M, Godos J, Riccardi G, Grosso G. Whole grain intake and glycaemic control in healthy subjects: a systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2017;9(7):769.

30.   Liu F, Prabhakar M, Ju J, Long H, Zhou H. Effect of inulin-type fructans on blood lipid profile and glucose level: a systematic review and meta-analysis of randomized controlled trials. *European journal of clinical nutrition*. 2017;71(1):9-20.

31.   Wang Y, Chen J, Song Y-H, et al. Effects of the resistant starch on glucose, insulin, insulin resistance, and lipid parameters in overweight or obese adults: a systematic review and meta-analysis. *Nutrition & diabetes*. 2019;9(1):1-11.

32.   Rao M, Gao C, Xu L, et al. Effect of inulin-type carbohydrates on insulin resistance in patients with type 2 diabetes and obesity: a systematic review and meta-analysis. *Journal of diabetes research*. 2019;2019

33.   Ojo O, Feng Q-Q, Ojo OO, Wang X-H. The role of dietary fibre in modulating gut microbiota dysbiosis in patients with Type 2 Diabetes: A systematic review and meta-analysis of randomised controlled trials. *Nutrients*. 2020;12(11):3239.

34.   Tabrizi R, Moosazadeh M, Lankarani KB, et al. The effects of synbiotic supplementation on glucose metabolism and lipid profiles in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. *Probiotics and antimicrobial proteins*. 2018;10(2):329-342.

35.   Akbari V, Hendijani F. Effects of probiotic supplementation in patients with type 2 diabetes: systematic review and meta-analysis. *Nutrition reviews*. 2016;74(12):774-784.

36.   Wang X, Juan Q-F, He Y-W, Zhuang L, Fang Y-Y, Wang Y-H. Multiple effects of probiotics on different types of diabetes: a systematic review and meta-analysis of randomized, placebo-controlled trials. *Journal of Pediatric Endocrinology and Metabolism*. 2017;30(6):611-622.

37.   Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS medicine*. 2009;6(7):e1000097.

38.   *EndNote*. Version EndNote X9. Clarivate; 2013.

39.   Knopp JL, Holder-Pearson L, Chase JG. Insulin units and conversion factors: a story of truth, boots, and faster half-truths. *Journal of diabetes science and technology*. 2019;13(3):597-600.

40.   Burnier P, Tappy L, Jequier E, Schneeberger D, Chiolero R. Metabolic and respiratory effects of infused sodium acetate in healthy human subjects. *American Journal of Physiology-Regulatory, Integrative and Comparative Physiology*. 1992;263(6):R1271-R1276.

41.   Akamine Y, Millman JF, Uema T, et al. Fermented brown rice beverage distinctively modulates the gut microbiota in Okinawans with metabolic syndrome: A randomized controlled trial. *Nutr Res*. Jul 2022;103:68-81. doi:10.1016/j.nutres.2022.03.013

42.   Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. *Cochrane handbook for systematic reviews of interventions*. 2019:205-228.

43.   *Review Manager* Version 5.4. 2020.

44.   Ding H, Hu GL, Zheng XY, Chen Q, Threapleton DE, Zhou ZH. The method quality of cross-over studies involved in Cochrane Systematic Reviews. *PloS one*. 2015;10(4):e0120519.

45.   Alles MS, de Roos NM, Bakx JC, van de Lisdonk E, Zock PL, Hautvast JG. Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. *The American journal of clinical nutrition*. 1999;69(1):64-69.

46.   Ampatzoglou A, Atwal KK, Maidens CM, et al. Increased whole grain consumption does not affect blood biochemistry, body composition, or gut microbiology in healthy, low-habitual whole grain consumers. *The Journal of nutrition*. 2015;145(2):215-221.

47.   Byrne CS, Chambers ES, Preston T, et al. Effects of inulin propionate ester incorporated into palatable food products on appetite and resting energy expenditure: a randomised crossover study. *Nutrients*. 2019;11(4):861.

48.   Canfora EE, van der Beek CM, Hermes GD, et al. Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. *Gastroenterology*. 2017;153(1):87-97. e3.

49.   Chambers ES, Byrne CS, Morrison DJ, et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. *Gut*. 2019;68(8):1430-1438.

50.   Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. *Gut*. 2015;64(11):1744-1754.

51.   Fava F, Gitau R, Griffin BA, Gibson G, Tuohy K, Lovegrove J. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. *International journal of obesity*. 2013;37(2):216-223.

52.   Giacco R, Clemente G, Luongo D, et al. Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolaemic individuals. *Clinical nutrition*. 2004;23(3):331-340.

53.   González Hernández MA, Canfora EE, Pasmans K, Astrup A, Saris W, Blaak EE. The Relationship between Circulating Acetate and Human Insulin Resistance before and after Weight Loss in the DiOGenes Study. *Nutrients*. 2020;12(2):339.

54.   Härma M-A, Adeshara K, Istomin N, et al. Gastrointestinal manifestations after Roux-en-Y gastric bypass surgery in individuals with and without type 2 diabetes. *Surgery for Obesity and Related Diseases*. 2021;17(3):585-594.

55.   Johnstone AM, Kelly J, Ryan S, et al. Nondigestible carbohydrates affect metabolic health and gut microbiota in overweight adults after weight loss. *The Journal of nutrition*. 2020;150(7):1859-1870.

56.   Maki KC, Pelkman CL, Finocchiaro ET, et al. Resistant starch from high-amylose maize increases insulin sensitivity in overweight and obese men. *The Journal of nutrition*. 2012;142(4):717-723.

57.   McIntosh GH, Noakes M, Royle PJ, Foster PR. Whole-grain rye and wheat foods and markers of bowel health in overweight middle-aged men. *The American journal of clinical nutrition.* 2003;77(4):967-974.

58.   Meslier V, Laiola M, Roager HM, et al. Mediterranean diet intervention in overweight and obese subjects lowers plasma cholesterol and causes changes in the gut microbiome and metabolome independently of energy intake. *Gut.* 2020;69(7):1258-1268.

59.   Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. *Nature Medicine.* 2021;27(7):1272-1279.

60.   Palacios T, Vitetta L, Coulson S, et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: a randomised controlled pilot study. *Nutrients.* 2020;12(7):2041.

61.   Sandberg JC, Björck IM, Nilsson AC. Rye-based evening meals favorably affected glucose regulation and appetite variables at the following breakfast; a randomized controlled study in healthy subjects. *PLoS One.* 2016;11(3):e0151985.

62.   Sandberg JC, Björck IM, Nilsson AC. Impact of rye-based evening meals on cognitive functions, mood and cardiometabolic risk factors: a randomized controlled study in healthy middle-aged subjects. *Nutrition journal.* 2018;17(1):1-14.

63.   Vetrani C, Costabile G, Luongo D, et al. Effects of whole-grain cereal foods on plasma short chain fatty acid concentrations in individuals with the metabolic syndrome. *Nutrition.* 2016;32(2):217-221.

64.   Chambers ES, Byrne CS, Rugyendo A, et al. The effects of dietary supplementation with inulin and inulin□propionate ester on hepatic steatosis in adults with non□alcoholic fatty liver disease. *Diabetes, Obesity and Metabolism.* 2019;21(2):372-376.

65.   Oh MR, Jang HY, Lee SY, et al. Lactobacillus plantarum HAC01 Supplementation Improves Glycemic Control in Prediabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Trial. *Nutrients.* Jul 8 2021;13(7)doi:10.3390/nu13072337

66.   Holst JJ, Ørskov C. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism. *Diabetes.* 2004;53(suppl 3):S197-S204.

67.   Richards RH, Vreman HJ, Zager P, Feldman C, Blaschke T, Weiner MW. Acetate metabolism in normal human subjects. *American Journal of Kidney Diseases.* 1982;2(1):47-57.

68.   Nitenberg A, Huyghebaert M-F, Blanchet F, Amiel C. Analysis of increased myocardial contractility during sodium acetate infusion in humans. *Kidney international.* 1984;26(5):744-751.

69.   Ekblad H, Kero P, Takala J. Slow sodium acetate infusion in the correction of metabolic acidosis in premature infants. *American journal of diseases of children.* 1985;139(7):708-710.

70.   Suokas A, Kupari M, Heikkilä J, Lindros K, Ylikahri R. Acute cardiovascular and metabolic effects of acetate in men. *Alcoholism: Clinical and Experimental Research.* 1988;12(1):52-58.

71.   Cherta-Murillo A, Pugh JE, Alaraj-Alshehhi S, Hajjar D, Chambers ES, Frost GS. The effects of SCFAs on glycemic control in humans: a systematic review and meta-analysis. *Am J Clin Nutr.* Aug 4 2022;116(2):335-361. doi:10.1093/ajcn/nqac085

72.   Fernandes J, Su W, Rahat-Rozenbloom S, Wolever TM, Comelli EM. Adiposity, gut microbiota and faecal short chain fatty acids are linked in adult humans. *Nutr Diabetes.* Jun 30 2014;4:e121. doi:10.1038/nutd.2014.23

73.   Canfora EE, Jocken JW, Blaak EE. Short-chain fatty acids in control of body weight and insulin sensitivity. *Nat Rev Endocrinol.* Oct 2015;11(10):577-91. doi:10.1038/nrendo.2015.128

74.   Muller M, Hernandez MAG, Goossens GH, et al. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. *Sci Rep.* Aug 29 2019;9(1):12515. doi:10.1038/s41598-019-48775-0

75.   Sowah SA, Riedl L, Damms-Machado A, et al. Effects of Weight-Loss Interventions on Short-Chain Fatty Acid Concentrations in Blood and Feces of Adults: A Systematic Review. *Adv Nutr*. Jul 1 2019;10(4):673-684. doi:10.1093/advances/nmy125

76.   Hanselman EC, Amado NJ, Breslin PAS. Oral Signals of Short and Long Chain Fatty Acids: Parallel Taste Pathways to Identify Microbes and Triglycerides. *Curr Opin Physiol*. Apr 2021;20:126-133. doi:10.1016/j.cophys.2021.01.008

77.   Gill PA, van Zelm MC, Muir JG, Gibson PR. Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders. *Aliment Pharmacol Ther*. Jul 2018;48(1):15-34. doi:10.1111/apt.14689

78.   Jensen AB, Sorensen TI, Pedersen O, Jess T, Brunak S, Allin KH. Increase in clinically recorded type 2 diabetes after colectomy. *Elife*. Oct 30 2018;7doi:10.7554/eLife.37420

79.   Eissele R, Goke R, Willemer S, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. *Eur J Clin Invest*. Apr 1992;22(4):283-91. doi:10.1111/j.1365-2362.1992.tb01464.x

Legend:

Table 1: PICOS criteria for inclusion and exclusion of studies analysed in this systematic review and meta-analysis. PICOS stands for participants, intervention, comparison, outcomes, and study design.

Table 2: Summary of studies included in the meta-analysis, which details study design, intervention, duration, dose, participant information as well as changes and source of SCFAs. The age, weight or BMI values are reported as per the original article. The effects of the intervention on glucose-insulin parameters are highlighted.

Figure 1: Study flow chart (PRISMA) diagram summarizing the process for the selection of papers for the analysis of the effects of SCFAs on fasting insulin, fasting glucose and HOMA-IR.

Figure 2: Fasting insulin concentrations from each study were compared between placebo and treatment at the endpoint (end of intervention period). Data were presented as SMD of fasting insulin (µU/mL) and were separated into two subgroups: one with evidence of an increase in SCFA concentration(s) post-intervention, and the other without any change in SCFAs post-intervention. The type of intervention (M: meal/mixed and C3: propionate) is noted at the end of each study. df: degrees of freedom, IV: inverse variance, CI: confidence interval.

Figure 3: Fasting glucose concentrations from each study were compared between placebo vs treatment at the endpoint (end of intervention period). Data were presented as SMD of fasting glucose (mmol/L) and were separated into two subgroups: one with evidence of an increase in SCFA concentration(s) post-intervention, and the other without any change in SCFAs post-intervention. The type of intervention (M: meal/mixed and C3: propionate) is noted at the end of each study. df: degrees of freedom, IV: inverse variance, CI: confidence interval.

Figure 4: HOMA-IR values were compared between the placebo and treatment at the endpoint (end of intervention period). Data were presented as SMD of HOMA-IR and separated into two subgroups: one with evidence of an increase in SCFA concentration(s) post-intervention, and the other without any change in SCFAs post-intervention. Type of intervention (M: meal/mixed and C3: propionate) is noted at the end of each study. df: degrees of freedom, IV: inverse variance, CI: confidence interval.

Figure 5: Fasting insulin concentrations at baseline and endpoint (end of intervention) from each study were compared in the treatment group. Data were presented as the SMD of fasting insulin (µU/mL) and were separated into two subgroups: one with evidence of an increase in SCFA concentration(s) post-intervention, and the other without any change in SCFAs post-intervention. Type of intervention (M: meal/mixed, C3: propionate and C2: acetate) is noted at the end of each study. df: degrees of freedom, IV: inverse variance, CI: confidence interval.

Figure 6: Fasting glucose concentrations at baseline and endpoint (end of intervention) from each study were compared in the treatment group. Data were presented as SMD of fasting insulin (mmol/L) and were separated into two subgroups: one with evidence of an increase in SCFA concentration(s) post-intervention, and the other without any change in SCFAs post-intervention. Type of intervention (M: meal/mixed, C3: propionate and C2: acetate) is noted at the end of each study. df: degrees of freedom, IV: inverse variance, CI: confidence interval.

Figure 7: HOMA-IR values at baseline and endpoint (end of intervention) from available studies were compared in the treatment group. Data were presented as SMD of HOMA-IR and were separated into two subgroups: one with evidence of an increase in SCFA concentration(s) post-intervention, and the other without any change in SCFAs post-intervention. Type of intervention (M: meal/mixed and C3: propionate) is noted at the end of each study. df: degrees of freedom, IV: inverse variance, CI: confidence interval.

Table 1: PICOS criteria to address the research question

	Inclusion	Exclusion
Participants	Healthy adults, obese/overweight adults, or adults with underlying conditions	No restriction on the human participants. Animal and *in vitro* cellular studies were excluded.
Interventions	Direct SCFA interventions (oral/IV infusion/enema of sodium acetate, propionate, or butyrate alone or mixed) or dietary supplementary (resistant starch, inulin, or chemically modifed fibres)	Direct supplementartion of substances other than three SCFAs (acetate, propionate or butyrate)
Comparators	Placebo vs intervention (endpoint); baseline vs endpoint (intervention group)	Two different treatments or doses or intermediate time points
Outcomes	The actual concentrations of fasting insulin, fasting glucose, or HOMA-IR as well as reporting of (actual concentration/bar graphs/in text) change in plasma or faecal levels of SCFAs at the end of intervention	Studies not reporting the concentrations of fasting insulin, fasting glucose, or HOMA-IR (such as AUCs, regression/correlation coefficients, bar graphs, difference in concentrations), AND not providing change in SCFAs
Study designs	Randomized Clinical Trials, crossover studies or treatment-only studies	Non-original papers (reviews, systematic reviews, conference reports, clinical trial protocols, ongoing studies) and Non-English papers

Table 2: Details of the 23 studies included in the meta-analysis

Study design	Authors (PMID), Country	Intervention, route, dosage, duration	Participants in Intervention group				Participants in Placebo group				Post-intervention SCFA levels (source, method)	Highlights
			Participants	Sex	Age (years)	BMI (kg/M^2) or Body mass (kg)	Participants	Sex	Age (years)	BMI (kg/M^2) or Body mass (kg)		
Treatment only	Burnier et al[40] 1992 (1481938), Switzerland	Sodium acetate, IV infusion, 0.5 M acetate (at rate of 2.5 mmol/min), 120 minutes	9 healthy individuals	6 males and 3 females	30±1	70±3 (kg)	-	-	-	-	↑ Acetate (Plasma, acetate kinase method)	Plasma insulin and glucose were not changed during acetate infusion.
	Fava et al[51] 2013 (22410962), UK	High saturated-fat diet, Diet, High saturated fat diet (HS) containing 38%E fat, 24 weeks	11 individuals with metabolic syndrome	N/A	54±9.5	28.8±4.9 (kg/m2)	-	-	-	-	All SCFAs ↑ (Faecal, GC-LS chromatography (FFAP column))	Fasting plasma glucose and insulin were not significantly altered after HS diet.
	Härma et al[54] 2021 (33246847), Finland	Gastric bypass (RYGB), Surgery, -, 6 months	30 obese (T2D and non-diabetic) individuals	9 males and 21 females	47.3±8.8	44.5±5.7 (kg/m2)	-	-	-	-	↓Acetate and ↓Butyrate, no change in Propionate (Faecal, GC-MS)	All individuals undergoing surgery had improved glycemic control.
	González et al[53] 2020 (32012996), Netherlands	Low-calorie diet, Diet, Low calorie diet with 800 kcal/d, 8 weeks	478 individuals with BMI≥27	175 males and 303 females	41±6	35±5 (kg/m2)	-	-	-	-	↑Acetate (Plasma, 1H NMR spectroscopy)	In ⌧, a positive association was observed between changes in acetate and changes in HOMA-IR
	Akamine et al[41] 2022 (35500381), Japan	White rice amazake (WA) OR brown rice amazake (BA), Diet, 350g/d, 4 weeks	19 individuals with metabolic syndrome (WA); 21 individuals with metabolic syndrome (BA)	11 males and 8 females (WA); 9 males and 12 females (BA)	56.7 ± 2.2 (WA); 58.5 ± 2.2 (BA)	28.8 ± 0.8 (WA); 28.8 ± 0.7 (BA)	-	-	-	-	No change in all SCFAs (Plasma, GC-LS chromatography)	Plasma glucose and plasma insulin were not significantly different between two treatments.
Randomised, placebo-controlled, parallel arm study	Chambers et al[50] 2015 (25500202), UK	Inulin propionate ester, Oral, 10g/d of inulin (control) vs 10g/d of inulin-propionate ester (intervention), 24 weeks	25 overweight individuals	10 males and 15 females	55.3±1.4	88.5±2.9 (kg)	24 overweight individuals	9 males and 15 females	53.4±1.5	91.0±2.8 (kg)	↑ Acetate, ↑ Propionate, no change in Butyrate (Faecal, GC-FID chromatography)	Fasting glucose, insulin & postprandial responses were not significantly different post-intervention.
	Vetrani et al[63] 2016 (26706023), Italy	Wholegrain diet, Diet, Refined cereal products (control) vs wholegrain cereal (intervention), 12 weeks	21 healthy individuals	9 males and 12 females	57.2±1.9	32.1±1.4 (kg/m2)	19 healthy individuals	7 males and 12 females	58.4±1.6	31.5±1.3 (kg/m2)	No change in Acetate and Butyrate, ↑ Propionate (Plasma, GC-MS chromatography)	Whole-grain wheat-based diet lowered postprandial insulin concentrations.
	Canfora et al[48] 2017 (28396144), Netherlands	Galacto-oligosaccharides, Diet, 16.95g/d maltodextrin (control) vs 15g/d Galacto-oligosaccharides (intervention), 12 weeks	21 obese or overweight individuals	11 males and 10 females	59.2±7.2	98.4±11.9 (kg)	23 obese or overweight individuals	12 males and 11 females	58.4±7.3	96.9±11.5 (kg)	No change in all SCFAs (Plasma and Faecal, GC-MS chromatography)	Intervention of galacto-oligosaccharides did not alter insulin sensitivity.
	Chambers et al[64] (2) 2019 (30098126), UK	Inulin propionate ester, Oral, 20g/d of inulin (control) vs 20g/d of inulin-propionate ester (intervention), 6 weeks	9 individuals with NAFLD	4 males and 5 females	51±4	31.5±1.9 (kg/m2)	9 individuals with non-alcoholic fatty liver disease	5 males and 4 females	49±4	29.5±1.4 (kg/m2)	No change in Acetate, Propionate but ↑ Butyrate (Plasma, 1H NMR spectroscopy)	The change in HOMA-IR was significantly different after intervention.

	Study	Intervention	Population (control)	Sex	Age	BMI	Population (intervention)	Sex	Age	BMI	SCFA findings	Glucose/insulin findings
	Palacios et al[60] 2020 (32660025), Australia	Probiotic, Oral, 200 mg microcrystalline cellulose+ 10 mg silica+ 10 mg magnesium stearate (control) vs multi-strain probiotic (intervention), 12 weeks	30 prediabetic or T2DM individuals	17 males and 13 females	61.4±8.9	35.5±6.2 (kg/m2)	30 prediabetic or T2DM individuals	11 males and 19 females	56.1±12.3	36.3±7.5 (kg/m2)	No change in all SCFAs (Plasma, GC-MS chromatography)	No significant differences in fasting plasma glucose (placebo Vs intervention).
	Meslier et al[58] 2020 (32075887), Italy	Mediterranean diet, Diet, Habitual diet (control) vs an individually tailored diet (intervention), 8 weeks	43 healthy overweight individuals	21 males and 22 females	43±13	30.9±3.8 (kg/m2)	39 healthy overweight individuals	18 males and 21 females	42±12	31.2±5.3 (kg/m2)	No change in all SCFAs (Faecal, GC-MS chromatography)	No changes were observed in blood glucose and plasma insulin concentrations.
	Oh et al[65] 2021 (34371847), Korea	Probiotic, Oral, one capsule daily of microcrystalline cellulose (control) vs one capsule daily of 4x10^9 CFU of L plantarum HA01 (intervention), 8 weeks	20 individuals with impaired glucose tolerance	6 males and 14 females	56.4±11.57	25.25±3.14 (kg/m2)	20 individuals with impaired glucose tolerance	3 males and 17 females	53.55±10.18	25.03±1.92 (kg/m2)	No change in all SCFAs (Faecal, LC-Triple Q-MS analysis)	Beneficial effect of single-strain probiotic supplementation administered over eight weeks on HbA1c levels in prediabetic subjects.
	Mocanu et al[59] 2021 (34226737), Canada	Fibre, Diet, 33g/d (♀) and 27g/d (♂) of microcrystalline cellulose (LF; control) vs same dose of corn fiber, resistant wheat starch type 4 & acacia gum (intervention), 6 weeks	15 obese individuals	2 males and 13 females	48.4±8.8	131.3±32.0 (kg)	17 obese individuals	5 males and 12 females	48.3±10.4	122.8±25.5 (kg)	No change in all SCFAs (Faecal, GC-FID chromatography)	No difference in HOMA-IR was observed between the baseline and at the end of intervention in the treatment group.
Randomised, single (PMID 9925124) or double blind (remaining), placebo-controlled, crossover study	Alles et al[45] 1999 (9925124), Netherlands	Fructo-oligosaccharides, Diet, 4g glucose/d (control) vs 15g of FOS/d (intervention), 20 days	20 T2D patients	9 males and 11 females	59.3±5.4	28.3±3.5 (kg/m2)	20 T2D patients	9 males and 11 females	59.3±5.4	28.3±3.5 (kg/m2)	No change in Acetate (Plasma, Enzymatic method)	Dietary supplementation did not change blood glucose in T2D.
	McIntosh et al[57] 2003 (12663299), Australia	High fibre wheat or rye vs Low fibre, Diet, 19g dietary fibre/d (control) vs 32g dietary fibre/d (intervention), 4 weeks	28 overweight	28 males	40–65	30±0.9 (kg/m2)	28 overweight	28 males	40–65	30±0.9 (kg/m2)	Unchanged Acetate, ↑ Propionate in high wheat group, ↑ Butyrate in high rye group (Faecal, GC-LC-MS chromatography)	Improved metabolic health & ↓plasma insulin in intervention compared to control.
	Sandberg et al[61] 2016 (26990559), Sweden	Rye-based diet, Diet, 100% white wheat flour bread (control) vs 85% whole rye kernels+15% white wheat flour bread (intervention), 1 or 3 consecutive meals	19 healthy recruits; data on 18 subjects	9 males and 10 females	25.6 ± 3.5	21.9 ± 1.87 kg/m2	19 healthy individuals recruited and data available for 17 subjects	9 males and 10 females	25.6 ± 3.5	21.9 ± 1.87 kg/m2	All SCFAs ↑ (Plasma, GC chromatography)	Rye kernel-based meal ↓ glycemia and improved insulin sensitivity.
	Sandberg et al[62] 2018 (30400947), Sweden	Rye-kernel and resistant starch type 2, Diet, 100% white wheat flour bread (control) vs 43% rye kernels+ 43% whole grain rye flour + 14% HAMRS2 flour bread (intervention), 3 days	38 healthy individuals	8 males and 30 females	63.9±5.5	24.2±2.5 (kg/m2)	38 healthy individuals	8 males and 30 females	63.9±5.5	24.2±2.5 (kg/m2)	All SCFAs ↑ (Plasma, GC-MS chromatography)	Wholegrain rye-based bread ↑ insulin sensitivity, and fasting SCFAs but not fasting insulin, and fasting glucose.

Study	Intervention	Control group	Sex	Age	BMI/Weight	Intervention group	Sex	Age	BMI/Weight	SCFA result	Outcome
Johnstone et al[55] 2020 (32510158), UK	Resistant starch, Diet, 22g/d for females and 26 g/d for males of digestible starch (control) vs 22g/d for females and 26 g/d for males of resistant starch type 3 (intervention), 10 days	19 obese or overweight individuals	11 males and 8 females	20-62	94.3±18.5 (kg)	19 obese or overweight individuals	11 males and 8 females	20-62	94.3±18.5 (kg)	No change in all SCFAs (Faecal, Capillary GC-MS chromatography)	Fasting blood glucose but not insulin was lower in resistant starch diet.
Ampatzoglou et al[46] 2015 (25644340), UK	Wholegrain diet, Diet, <16g/d (control) vs >80g/d of wholegrain (intervention), 6 weeks	33 healthy subjects	12 males and 21 females	48.8±1.1	27.9±0.7 (kg/m2)	33 healthy subjects	12 males and 21 females	48.8±1.1	27.9±0.7 (kg/m2)	No change in all SCFAs (Faecal, HPLC)	No significant changes in fecal SCFAs or blood glucose following wholegrain consumption.
Giacco et al[52] 2004 (15158296), Italy	Short-chain fructooligosaccharides, Diet, 15g/d (placebo) vs 10.6g/d of sc-FOS (intervention), 2 months	30 patients with mild hypercholesterolaemia	20 males and 10 females	45.5±9.9	26.6±2.2 (kg/m2)	30 patients with mild hypercholesterolaemia	20 males and 10 females	45.5±9.9	26.6±2.2 (kg/m2)	No change in Acetate (Plasma, GC-MS chromatography)	Postprandial insulin response (but not glucose) significantly ↓post-intervention.
Maki et al[56] 2012 (22357745), USA	Resistant starch type 2, Diet, 0g/d (control) vs 30g/d of HAM-RS2 (intervention), 4 weeks	33 overweight or obese individuals	11 males and 22 females	49.5±1.6	30.6±0.5 (kg/m2)	33 overweight or obese individuals	11 males and 22 females	49.5±1.6	30.6±0.5 (kg/m2)	↑ (in females), No change in Propionate/Butyrate (Plasma, GC chromatography)	Insulin sensitivity improved in males but not in females.
Chambers et al[49] 2019 (30971437), UK	Inulin propionate ester, Oral, 20g/d cellulose (control) vs 20g/d inulin-propionate ester (intervention), 6 weeks	12 nondiabetic individuals with obesity or overweight	3 males and 9 females	60±1	29.8±0.9 (kg/m2)	12 nondiabetic individuals with obesity or overweight	3 males and 9 females	60±1	29.8±0.9 (kg/m2)	No change in all SCFAs (Plasma, 1H NMR spectroscopy)	Colonic propionate delivery via inulin-propionate ester improves insulin sensitivity.
Byrne et al[47] 2019 (30995824), UK	Inulin propionate ester, Oral, 10g/d of inulin (control) vs 10g/d of inulin-propionate ester (intervention), 6 days	21 healthy individuals with obesity or overweight	9 males and 12 females	59±8	81.5±9 (kg)	21 healthy individuals with obesity or overweight	9 males and 12 females	59±8	81.5±9 (kg)	No change in all SCFAs (Plasma, GC-MS chromatography)	No change in baseline values or AUC for glucose and insulin after intervention.

Figure 1: Study flow chart (PRISMA) diagram

Figure 2: Forest plot of fasting insulin concentrations between control and treatment

Study or Subgroup	Treatment Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year	Std. Mean Difference IV, Random, 95% CI
1.6.1 Papers with increased SCFAs										
McIntosh(a) et al 2003, M	6.08	3.7	28	6.83	4.3	28	7.3%	-0.18 [-0.71, 0.34]	2003	
McIntosh(b) et al 2003, M	6.65	4.1	28	6.83	4.3	28	7.3%	-0.04 [-0.57, 0.48]	2003	
Maki(b) et al 2012, M	7.6	3.9	22	9.4	3.9	22	5.6%	-0.45 [-1.05, 0.15]	2012	
Chambers et al 2015, C3	8.8	4	25	10.6	3.4	24	6.2%	-0.48 [-1.04, 0.09]	2015	
Vetrani et al 2016, M	13.3	5	21	11.7	7	19	5.1%	0.26 [-0.36, 0.88]	2016	
Sandberg et al 2016, M	5.17	1.33	19	5.33	1.33	19	4.9%	-0.12 [-0.75, 0.52]	2016	
Sandberg et al 2017, M	5.5	1.67	38	6	1.67	38	9.8%	-0.30 [-0.75, 0.16]	2017	
Chambers et al 2019, C3	9.4	4.2	12	12.3	4.8	12	3.0%	-0.62 [-1.44, 0.20]	2019	
Chambers et al 2019(2),C3	7.9	5.1	9	15.3	10.5	9	2.1%	-0.85 [-1.83, 0.12]	2019	
Palacios et al 2020, M	10.4	5.4	30	12.4	11.2	30	7.8%	-0.22 [-0.73, 0.28]	2020	
Subtotal (95% CI)			**232**			**229**	**59.0%**	**-0.25 [-0.43, -0.06]**		

Heterogeneity: Tau² = 0.00; Chi² = 6.75, df = 9 (P = 0.66); I² = 0%
Test for overall effect: Z = 2.64 (P = 0.008)

Study or Subgroup	Treatment Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year	Std. Mean Difference IV, Random, 95% CI
1.6.2 Papers without increased SCFAs										
Giacco et al 2004, M	8.6	2.5	27	8.4	1.8	27	7.0%	0.09 [-0.44, 0.62]	2004	
Maki(a) et al 2012, M	9.75	2.6	11	10.42	2.6	11	2.8%	-0.25 [-1.09, 0.59]	2012	
Canfora et al 2017, M	18.9	8.3	21	18.3	10.1	23	5.7%	0.06 [-0.53, 0.66]	2017	
Byrne et al 2019, C3	2.4	0.3	21	2.4	0.3	21	5.5%	0.00 [-0.60, 0.60]	2019	
Meslier et al 2020, M	17	8.6	43	16.7	8.4	39	10.6%	0.03 [-0.40, 0.47]	2020	
Johnstone et al 2020, M	21.6	11.33	18	20.14	7.46	18	4.7%	0.15 [-0.51, 0.80]	2020	
Oh et al 2021, M	9.53	4.05	20	11.44	6.17	17	4.7%	-0.36 [-1.02, 0.29]	2021	
Subtotal (95% CI)			**161**			**156**	**41.0%**	**-0.01 [-0.23, 0.21]**		

Heterogeneity: Tau² = 0.00; Chi² = 1.91, df = 6 (P = 0.93); I² = 0%
Test for overall effect: Z = 0.08 (P = 0.94)

Total (95% CI)			**393**			**385**	**100.0%**	**-0.15 [-0.29, -0.01]**		

Heterogeneity: Tau² = 0.00; Chi² = 11.32, df = 16 (P = 0.79); I² = 0%
Test for overall effect: Z = 2.08 (P = 0.04)
Test for subgroup differences: Chi² = 2.67, df = 1 (P = 0.10), I² = 62.5%

Favours [Treatment] Favours [Placebo]

Figure 3: Forest plot of fasting glucose concentrations between control and treatment

Study or Subgroup	Treatment Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year	Std. Mean Difference IV, Random, 95% CI
2.6.1 Papers with increased SCFAs										
McIntosh(a) et al 2003, M	5.6	0.9	28	5.64	0.85	28	6.6%	-0.05 [-0.57, 0.48]	2003	
McIntosh(b) et al 2003, M	5.59	0.7	28	5.64	0.85	28	6.6%	-0.06 [-0.59, 0.46]	2003	
Maki(b) et al 2012, M	5.4	0.47	22	5.5	0.47	22	5.1%	-0.21 [-0.80, 0.38]	2012	
Chambers et al 2015, C3	5	0.5	25	5	0.5	24	5.7%	0.00 [-0.56, 0.56]	2015	
Vetrani et al 2016, M	5.7	0.7	21	5.8	0.1	19	4.7%	-0.19 [-0.81, 0.43]	2016	
Sandberg et al 2016, M	5.2	0.4	18	5.1	0.4	17	4.1%	0.24 [-0.42, 0.91]	2016	
Sandberg et al 2017, M	5.7	0.6	38	5.7	0.6	38	8.9%	0.00 [-0.45, 0.45]	2017	
Chambers et al 2019, C3	5.3	0.4	12	5.2	0.7	12	2.8%	0.17 [-0.63, 0.97]	2019	
Chambers et al 2019(2),C3	5.9	0.9	9	6.3	1.2	9	2.1%	-0.36 [-1.29, 0.57]	2019	
Palacios et al 2020, M	5.7	0.6	30	5.8	0.7	30	7.0%	-0.15 [-0.66, 0.36]	2020	
Subtotal (95% CI)			231			227	53.5%	-0.06 [-0.24, 0.13]		

Heterogeneity: Tau² = 0.00; Chi² = 2.16, df = 9 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.60 (P = 0.55)

Study or Subgroup	Treatment Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year	Std. Mean Difference IV, Random, 95% CI
2.6.2 Papers without increased SCFAs										
Alles et al 1999, M	8.61	2.61	20	8.59	2.66	20	4.7%	0.01 [-0.61, 0.63]	1999	
Giacco et al 2004, M	5.44	1	27	5.38	0.83	27	6.3%	0.06 [-0.47, 0.60]	2004	
Ampatzoglou et al 2015, M	5.4	0.6	33	5.4	0.6	33	7.7%	0.00 [-0.48, 0.48]	2015	
Canfora et al 2017, M	6	0.5	21	5.8	0.5	23	5.0%	0.39 [-0.20, 0.99]	2017	
Byrne et al 2019, C3	5.3	0.5	21	5.5	0.4	21	4.8%	-0.43 [-1.05, 0.18]	2019	
Johnstone et al 2020, M	5.59	0.31	18	5.84	0.57	18	4.1%	-0.53 [-1.20, 0.13]	2020	
Meslier et al 2020, M	5.31	0.47	43	5.2	0.56	39	9.5%	0.21 [-0.22, 0.65]	2020	
Oh et al 2021, M	5.4	0.5	20	5.6	0.6	17	4.2%	-0.36 [-1.01, 0.30]	2021	
Subtotal (95% CI)			203			198	46.5%	-0.04 [-0.25, 0.18]		

Heterogeneity: Tau² = 0.01; Chi² = 8.08, df = 7 (P = 0.33); I² = 13%
Test for overall effect: Z = 0.33 (P = 0.74)

Total (95% CI)			434			425	100.0%	-0.04 [-0.18, 0.09]		

Heterogeneity: Tau² = 0.00; Chi² = 10.28, df = 17 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.89), I² = 0%

-4 -2 0 2 4
Favours [Treatment]   Favours [Placebo]

Figure 4: Forest plot of HOMA-IR values between control and treatment

Study or Subgroup	Treatment Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
4.1.1 Papers with increased SCFAs									
Vetrani et al 2016, M	3.36	1.37	21	3.09	2.18	19	10.9%	0.15 [-0.47, 0.77]	2016
Sandberg et al 2017, M	1.4	0.6	38	1.5	0.6	38	20.8%	-0.16 [-0.62, 0.29]	2017
Chambers et al 2019(2),C3	2.2	1.8	9	4.5	3.6	9	4.5%	-0.77 [-1.74, 0.20]	2019
Chambers et al 2019, C3	1.23	0.59	12	1.59	0.59	12	6.3%	-0.59 [-1.41, 0.23]	2019
Palacios et al 2020, M	2.7	1.5	30	3.3	3.3	30	16.4%	-0.23 [-0.74, 0.28]	2020
Subtotal (95% CI)			**110**			**108**	**58.9%**	**-0.22 [-0.48, 0.05]**	

Heterogeneity: Tau² = 0.00; Chi² = 3.42, df = 4 (P = 0.49); I² = 0%
Test for overall effect: Z = 1.59 (P = 0.11)

Study or Subgroup	Treatment Mean	SD	Total	Placebo Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
4.1.2 papers without increased SCFAs									
Meslier et al 2020, M	4.02	2.16	43	3.7	1.8	39	22.4%	0.16 [-0.28, 0.59]	2020
Mocanu et al 2021, M	3.49	5.54	15	3.76	8.66	17	8.8%	-0.04 [-0.73, 0.66]	2021
Oh et al 2021, M	2.35	1.1	20	2.91	1.6	17	9.9%	-0.41 [-1.06, 0.25]	2021
Subtotal (95% CI)			**78**			**73**	**41.1%**	**-0.02 [-0.34, 0.30]**	

Heterogeneity: Tau² = 0.00; Chi² = 1.99, df = 2 (P = 0.37); I² = 0%
Test for overall effect: Z = 0.11 (P = 0.91)

| **Total (95% CI)** | | | **188** | | | **181** | **100.0%** | **-0.14 [-0.34, 0.07]** | |

Heterogeneity: Tau² = 0.00; Chi² = 6.27, df = 7 (P = 0.51); I² = 0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi² = 0.87, df = 1 (P = 0.35), I² = 0%

Favours [Treatment] Favours [Placebo]

Figure 5: Forest plot of fasting insulin concentrations between baseline and endpoint in treatment group

	Endpoint			Baseline				Std. Mean Difference		Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
1.8.1 Papers with increased SCFAs										
Burnier et al 1992, C2	5	1.2	9	4.4	1.2	9	2.5%	0.48 [-0.46, 1.42]	1992	
Fava et al 2013, M	12.13	13.4	88	12.93	15.63	88	14.8%	-0.05 [-0.35, 0.24]	2013	
Chambers et al 2015, C3	8.8	4	25	9	5	25	6.3%	-0.04 [-0.60, 0.51]	2015	
Vetrani et al 2016, M	13.3	5	21	14.1	8.3	21	5.4%	-0.11 [-0.72, 0.49]	2016	
Chambers et al 2019(2),C3	7.9	5.1	9	9.1	6	9	2.6%	-0.21 [-1.13, 0.72]	2019	
Palacios et al 2020, M	10.4	5.4	30	12.8	6.5	30	7.1%	-0.40 [-0.91, 0.11]	2020	
González et al 2020, M	8.2	8.1	478	12.1	10.1	478	26.5%	-0.43 [-0.55, -0.30]	2020	
Subtotal (95% CI)			660			660	65.3%	-0.22 [-0.43, -0.01]		

Heterogeneity: Tau² = 0.03; Chi² = 9.94, df = 6 (P = 0.13); I² = 40%
Test for overall effect: Z = 2.06 (P = 0.04)

	Endpoint			Baseline				Std. Mean Difference		Std. Mean Difference
1.8.2 Papers without increased SCFAs										
Canfora et al 2017, M	18.9	8.3	21	20.7	8.8	21	5.4%	-0.21 [-0.81, 0.40]	2017	
Johnstone et al 2020, M	21.6	11.33	18	17.62	6.54	18	4.7%	0.42 [-0.24, 1.08]	2020	
Meslier et al 2020, M	17.1	8.6	43	18.5	10.7	43	9.5%	-0.14 [-0.57, 0.28]	2020	
Oh et al 2021, M	9.53	4.05	20	11.44	6.17	17	4.8%	-0.36 [-1.02, 0.29]	2021	
Akamine (a) et al 2022, M	9.3	4.79	19	10.5	7.85	19	5.0%	-0.18 [-0.82, 0.46]	2022	
Akamine (b) et al 2022, M	10.1	4.58	21	10	4.58	21	5.4%	0.02 [-0.58, 0.63]	2022	
Subtotal (95% CI)			142			139	34.7%	-0.09 [-0.33, 0.14]		

Heterogeneity: Tau² = 0.00; Chi² = 3.38, df = 5 (P = 0.64); I² = 0%
Test for overall effect: Z = 0.75 (P = 0.45)

	Endpoint			Baseline				Std. Mean Difference		
Total (95% CI)			802			799	100.0%	-0.18 [-0.34, -0.03]		

Heterogeneity: Tau² = 0.02; Chi² = 16.72, df = 12 (P = 0.16); I² = 28%
Test for overall effect: Z = 2.31 (P = 0.02)
Test for subgroup differences: Chi² = 0.64, df = 1 (P = 0.42), I² = 0%

-2   -1   0   1   2
Favours [Endpoint]   Favours [Baseline]

Figure 6: Forest plot of fasting glucose concentrations between baseline and endpoint in treatment group

Study or Subgroup	Endpoint Mean	SD	Total	Baseline Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
2.8.1 Papers with increased SCFAs									
Burnier et al 1992, C2	5.2	0.5	9	5.4	0.3	9	1.8%	-0.46 [-1.40, 0.48]	1992
Maki(b) et al 2012, M	5.4	0.47	22	5.29	0.47	22	4.1%	0.23 [-0.36, 0.82]	2012
Fava et al 2013, M	5.2	0.3	88	5.2	0.4	88	11.1%	0.00 [-0.30, 0.30]	2013
Chambers et al 2015, C3	5	0.5	25	5	0.5	25	4.6%	0.00 [-0.55, 0.55]	2015
Vetrani et al 2016, M	5.7	0.7	21	5.7	0.6	21	4.0%	0.00 [-0.60, 0.60]	2016
Sandberg et al 2017, M	5.7	0.6	38	5.7	0.4	38	6.4%	0.00 [-0.45, 0.45]	2017
Chambers et al 2019(2),C3	5.9	0.9	9	6.1	1.2	9	1.9%	-0.18 [-1.11, 0.75]	2019
Palacios et al 2020, M	5.7	0.6	30	5.9	0.8	30	5.3%	-0.28 [-0.79, 0.23]	2020
González et al 2020, M	4.9	0.4	478	5.1	0.6	478	20.1%	-0.39 [-0.52, -0.26]	2020
Subtotal (95% CI)			**720**			**720**	**59.4%**	**-0.15 [-0.33, 0.03]**	
Heterogeneity: Tau² = 0.02; Chi² = 12.68, df = 8 (P = 0.12); I² = 37%									
Test for overall effect: Z = 1.61 (P = 0.11)									
2.8.2 Papers without increased SCFAs									
Alles et al 1999, M	8.61	2.61	20	8.41	2	20	3.8%	0.08 [-0.54, 0.70]	1999
Ampatzoglou et al 2015, M	5.4	0.6	33	5.5	0.6	33	5.7%	-0.16 [-0.65, 0.32]	2015
Canfora et al 2017, M	6	0.5	21	6	0.5	21	4.0%	0.00 [-0.60, 0.60]	2017
Meslier et al 2020, M	5.31	0.47	43	5.2	0.58	43	7.0%	0.21 [-0.22, 0.63]	2020
Härma et al 2020	5.8	1.2	30	6.6	1.2	30	5.1%	-0.66 [-1.18, -0.14]	2020
Johnstone et al 2020, M	5.59	0.31	18	5.62	0.58	18	3.5%	-0.06 [-0.72, 0.59]	2020
Oh et al 2021, M	5.4	0.5	20	5.5	0.3	20	3.8%	-0.24 [-0.86, 0.38]	2021
Akamine (a) et al 2022, M	6.2	1.31	19	6.3	0.87	19	3.7%	-0.09 [-0.72, 0.55]	2022
Akamine (b) et al 2022, M	5.7	0.92	21	5.6	0.92	21	4.0%	0.11 [-0.50, 0.71]	2022
Subtotal (95% CI)			**225**			**225**	**40.6%**	**-0.08 [-0.27, 0.10]**	
Heterogeneity: Tau² = 0.00; Chi² = 7.56, df = 8 (P = 0.48); I² = 0%									
Test for overall effect: Z = 0.89 (P = 0.37)									
Total (95% CI)			**945**			**945**	**100.0%**	**-0.13 [-0.26, 0.00]**	
Heterogeneity: Tau² = 0.02; Chi² = 23.20, df = 17 (P = 0.14); I² = 27%									
Test for overall effect: Z = 1.96 (P = 0.05)									
Test for subgroup differences: Chi² = 0.25, df = 1 (P = 0.62), I² = 0%									

Favours [Endpoint]   Favours [Baseline]

Figure 7: Forest plot of HOMA-IR values between baseline and endpoint in treatment group

Study or Subgroup	Endpoint Mean	SD	Total	Baseline Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
4.2.1 Papers with increased SCFAs									
Vetrani et al 2016, M	3.36	1.37	21	3.61	2.29	21	3.3%	-0.13 [-0.74, 0.48]	2016
Chambers et al 2019(2),C3	2.2	1.8	9	2.6	2.1	9	1.4%	-0.19 [-1.12, 0.73]	2019
González et al 2020, M	2.07	2.42	478	3.27	2.81	478	72.5%	-0.46 [-0.59, -0.33]	2020
Palacios et al 2020, M	2.7	1.5	30	3.4	1.9	30	4.6%	-0.40 [-0.92, 0.11]	2020
Subtotal (95% CI)			538			538	81.7%	-0.44 [-0.56, -0.32]	

Heterogeneity: Tau² = 0.00; Chi² = 1.36, df = 3 (P = 0.71); I² = 0%
Test for overall effect: Z = 7.08 (P < 0.00001)

Study or Subgroup	Endpoint Mean	SD	Total	Baseline Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
4.2.2 Papers without increased SCFAs									
Meslier et al 2020, M	4.02	2.16	43	4.5	3	43	6.7%	-0.18 [-0.61, 0.24]	2020
Mocanu et al 2021, M	3.49	5.54	15	3.26	5.15	15	2.3%	0.04 [-0.67, 0.76]	2021
Oh et al 2021, M	2.35	1.1	20	2.36	1.06	20	3.1%	-0.01 [-0.63, 0.61]	2021
Akamine (a) et al 2022, M	2.5	1.31	19	2.9	2.18	19	2.9%	-0.22 [-0.86, 0.42]	2022
Akamine (b) et al 2022, M	2.6	1.37	21	2.6	1.37	21	3.3%	0.00 [-0.60, 0.60]	2022
Subtotal (95% CI)			118			118	18.3%	-0.10 [-0.35, 0.16]	

Heterogeneity: Tau² = 0.00; Chi² = 0.61, df = 4 (P = 0.96); I² = 0%
Test for overall effect: Z = 0.75 (P = 0.46)

Study or Subgroup	Endpoint Mean	SD	Total	Baseline Mean	SD	Total	Weight	Std. Mean Difference IV, Random, 95% CI	Year
Total (95% CI)			656			656	100.0%	-0.37 [-0.48, -0.27]	

Heterogeneity: Tau² = 0.00; Chi² = 7.51, df = 8 (P = 0.48); I² = 0%
Test for overall effect: Z = 6.72 (P < 0.00001)
Test for subgroup differences: Chi² = 5.54, df = 1 (P = 0.02), I² = 81.9%

Std. Mean Difference IV, Random, 95% CI
-4 -2 0 2 4
Favours [Endpoint] Favours [Baseline]